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Abstract
In favor of their outgrowth, cancer cells must resist immune surveillance and edit the immune response. Cancer
immunoediting is characterized by fundamental changes in the cellular composition and the inflammatory cytokine
profiles in the microenvironment of the primary tumor and metastatic niches, with an ever increasing complexity of
interactions between tumor cells and the immune system. Recent data suggest that genetic instability and
immunoediting are not necessarily disparate processes. Increasing mutational load may be associated with multiple
neoepitopes expressed by the tumor cells and thus increased chances for the immune system to recognize and
combat these cells. At the same time the immune system is more and more suppressed and exhausted by this
process. Consequently, immune checkpoint modulation may have the potential to be most successful in genetically
highly altered and usually extremely unfavorable types of cancer. Moreover, the fact that epitopes recognized by
the immune system are preferentially encoded by passenger gene mutations opens windows of synergy in
targeting cancer-specific signaling pathways by small molecules simultaneously with antibodies modifying T-cell
activation or exhaustion.
This review covers some aspects of the current understanding of the immunological basis necessary to understand
the rapidly developing therapeutic endeavours in cancer treatment, the clinical achievements made, and raises
some burning questions for translational research in this field.
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Background
Tumor immunotherapy has a long-standing history.
Starting with the work of William Coley in the 1890s
[1], some progress in the treatment of malignancies was
achieved with the introduction of interferons, interleukin-
2 given either systemically or used for in vitro expansion
of T-cells and reinfusion of lymphokine-activated killer
cells. At the price of substantial side effects, success was
seen in hematological cancers such as multiple myeloma,
follicular lymphoma and myeloproliferative disorders,
including chronic myeloid leukemia and polycythemia
vera (interferons) and acute myeloid leukemia (AML)
post allogeneic stem cell transplantation (interleukin-2)
[2, 3]. In solid cancers, including melanoma and renal
cell cancer, some long-term survivors and even cures
were observed with extremely high-dose immuno- or
chemoimmunotherapy approaches with interferons or
interleukin-2 in the metastatic setting, but toxicities
were severe [4, 5].
Substantial progress has later been made with the
introduction of monoclonal antibodies (MAb) inducing
apoptosis and/or eliciting antibody- or complement-
dependent cytotoxicity after binding to tumor antigens.
Just to name a few, anti-CD20- [6], anti-Her2- [7],
anti-epidermal growth factor receptor (EGFR)- [8] and
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anti-CD38-MAb [9] are highly efficient in the clinics.
Antibodies armed with toxins (eg brentuximab vedotin
[10], gemtuzumab ozogamicin [11], trastuzumab emtan-
sine [12], rovalpituzumab tesirine [13], denileukin diftitox
[14]) have also proven to be successful.
The most exciting recent progress in the treatment of
cancers, however, is derived from the better understand-
ing of how tumor cells escape immune recognition [15]
and how they exhaust, suppress and even kill immuno-
competent T-cells directed against the tumor [16–20].
T-cell exhaustion is thereby induced by consistent antigen
exposure leading to altered T-cell differentiation, loss of
effector functions and anergy as well as upregulation and
coexpression of inhibitory receptors that are also used as
exhaustion markers (eg programmed death 1 (PD1)), and
alterations of other key characteristics (for reviews see
[21–23]). In addition, cancer cells cleverly expand regula-
tory T-cells (Tregs) [24] and further B-, natural killer- and
dendritic-regulatory cells (for review see [25]) in order to
prime the microenvironment towards a tumor supportive
milieu. Under normal conditions, immune checkpoint
molecules serve to regulate T-cell responses, which is
necessary to avoid uncontrolled expansion resulting in
organ destruction and fatal outcomes. Tumor cells use
these intrinsic ‘brakes’ of the immune system as immune
escape mechanisms by inducing functionally exhausted
T-cells [15, 25].
The generality of these mechanisms across most -if
not all- cancer types implies a yet unexploited applicability
of drugs targeting immune suppression in a wide range of
tumor entities. In fact, antibodies counteracting suppres-
sion of the T-cell receptor (TCR) signaling via CD28/
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
(eg ipilimumab), or interfering with T-cell exhaustion
via the PD1/PD ligand 1 (PDL1) axis (eg nivolumab,
pembrolizumab, atezolizumab, durvalumab etc.) display
impressive therapeutic efficacy in melanoma [26–32],
squamous [33] and non-squamous non-small-cell lung
cancer (NSCLC) [34], squamous cell cancer of the head
and neck [35], renal [36], urothelial cancers [37] and
Hodgkin’s disase [38, 39]. Anticancer drugs targeting
these so-called ‘immune checkpoints’ on T-cells have been
termed ‘checkpoint inhibitors’. The opposite side of the
coin, however, is the relevant side effect profile of check-
point inhibitors, with some patients developing auto-
immunity against various organs including hypophysis,
adrenal glands, beta cells of the pancreas, thyroid, lungs,
liver, gut and nerves. In fact, knockout of PD1 [40] or
CTLA-4 [41] resulted in severe and lethal autoimmune
diseases in murine models. In humans, treatment with
anti-CTLA-4 or anti-PD1 MAbs led to significant auto-
immune phenomena and the number of patients with
treatment-related grade 3–4 side effects increased up to
55% when both drugs were combined [26].
There is need to systematically clarify the potential ex-
ploitation of targeting individual receptors expressed by
T-cells, with the aim of circumventing the immunosup-
pressive effects cleverly used by cancer cells to evade host
anti-tumor immune responses. In brief, T-cells exhibit
various activating and inhibitory ‘checkpoint’ receptors or
molecules (Fig. 1a).
Activating costimulatory immune checkpoint molecules
expressed by T-cells include (i) the B7-CD28 superfamily,
which encompasses CD28 (the receptor for CD80 and
CD86), CD278 (inducible T-cell costimulator (ICOS) and
TREML-2/TLT-2 (Trem-like transcript 2 protein), and (ii)
members of the tumor necrosis factor receptor (TNFR)
superfamily such as CD27, CD134 (OX40), CD137 (in-
duced by lymphocyte activation (ILA)), CD270 (herpes-
virus entry mediator (HVEM)) and CD357 (glucocorticoid-
induced TNFR family related gene (GITR)) (reviewed eg in
[42]).
Inhibitory checkpoint molecules found on T-cells in-
clude CD152 (CTLA-4), CD223 (lymphocyte activation
gene 3 (LAG3)), CD272 (B- and T-lymphocyte attenuator
(BTLA)), CD279 (PD1) and CD366 (T-cell immunoglobu-
lin and mucin protein 3 (TIM3)), V-domain Ig suppressor
of T-cell activation (VISTA), as well as the newly discov-
ered T-cell immunoreceptor with Ig and ITIM domains
(TIGIT).
These checkpoint molecules are extremely important,
as they help the body to discriminate between ‘foreign’
and ‘self ’ as well as help restrain immune responses against
foreign targets, while sparing ‘self ’. They are often deregu-
lated in cancer, eg by expression or upregulation of inhibi-
tory molecules by the cancer cells themselves, and/or by
production of soluble factors by the cancer cells that result
in downregulation or blockage of activating receptors, or
in ligation and/or upregulation of inhibitory receptors on
T-cells, respectively (Fig. 1b). In addition, the phenomenon
of T-cell exhaustion can be induced by cancer, thereby hin-
dering anti-tumor immune control (reviewed in [21, 22]).
Numerous drugs have been developed to intercept the
malignant control of the immune system by specifically
targeting these checkpoint molecules on T-cells. Activat-
ing checkpoint molecules can be therapeutically targeted
with agonistic molecules, whereas inhibitory immune
checkpoint molecules expressed by T-cells can be targeted
with blocking antibodies, and the respective drugs that are
currently tested and/or have been approved are listed in
Tables 1, 2, 3 and 4.
Predicting response to checkpoint blockade
The degree of efficacy of checkpoint inhibitors is highly
divergent between different tumor types. This phenomenon
may be attributed to differences in PDL1 expression on
neoplastic or microenvironmental cells, suggesting that this
marker should be quantified ahead of therapy. However,
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reported thresholds for PDL1 expression to predict
the probability of response towards anti-PD1 MAbs
vary between ≤ vs. >1% (for nivolumab) or ≤ vs. >50%
(for pembrolizumab) and ≤ vs. >1%, 5% or 10% (for
atezolizumab) with many reasons suggested, but none
being really convincing in explaining these differences
[43, 44]. Given the relevant side effect profiles of im-
mune checkpoint inhibitors and their exceptionally
A
B
Fig. 1 Checkpoint receptors on T cells. Figure 1a shows negative checkpoint receptors (NCRs) on the right, and activating (costimulatory) checkpoint
receptors (ACRs) of a normal T-cell on the left. The balance between the expression of these receptors, and the ligation with respective ligands,
determines the functional status of the T-cell during varying physiological processes. Figure 1b schematically shows how cancer cells may modulate
T-cells, to prefentretially express and upregulate NCRs. Therefore, T-cells of cancer patients often become exhausted, anergic, and/or incapable of
efficiently attacking and killing the cancer cells. This is one of the mechanisms by which the malignant cells induce tumor imune escape
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high costs, novel and better predictors of response are
therefore needed.
Notably, the mutational burden defined as the number
of mutations per megabase, may correlate with -and thus
predict the occurrence of- tumor-specific (neo)antigens
(TSA) which are expressed on the tumor cell surface
and presented to T-cells. T-cells exposed to TSA can
learn to specifically target and eliminate (ie kill) tumor
cells. In contrast to tumor-associated antigens (TAA),
which are in essence massively overexpressed ‘normal
antigens’ that also occur on normal, non-cancerous tis-
sues of the body, TSA are true neoantigens that cannot
be found on any non-malignant cell. TAA are much
more common than TSA, and strategies targeting TAA
molcules include eg the clinically widely successful tar-
geting of CD20 in lymphomas and CD33 in AML, as
briefly mentioned above. Targeting of TSA would in the-
ory eliminate the bystander killing of normal cells, which
also bear these molecules to a lesser extent (eg normal
B-cells or myeloid cells for the two molecules mentioned
above).
The mutational burden varies substantially over a range
of 3–4 logs in different tumor entities [45] and even
within the same tumor considerable interpatient variabil-
ity may be observed. Provided that in tumors with high
neoantigen frequency T cells are more prone to recognize
TSA, but are exhausted by specific ligands during immu-
noediting, strategies aimed at re-instating T cell functions
could be particularly effective in these patients [23]. This
view is supported by the following facts:
a) The response and efficacy of checkpoint inhibitors
seems to be highest in tumor types with the highest
mutational burden (eg melanoma, NSCLC) [46].
This is especially relevant in the light of the fact that
patients with high numbers of mutations are usually
weakly responsive to chemotherapy and/or rapidly
develop chemo-resistance.
b) In NSCLC patients treated with the PD1-inhibitor
pembrolizumab, progression-free survival massively
differed according to mutational burden in an as yet
unseen manner [47]. This has also been observed in
urothelial cancers treated with the anti-PDL1 antibody
atezolizumab [48].
c) Most patients with colon cancer usually do not
respond to checkpoint inhibitors [49], however, in a
small subset of advanced colorectal cancer patients
high microsatellite instability due to deficient DNA
mismatch repair [50] was observed, the occurrence
of which has been associated with a high number of
mutations, potentially resulting in an elevated
expression of TSA on the tumor cell surface [51].
Treatment of these patients with PD1-inhibitors
resulted in a response rate of nearly 40%, as
compared to only 11% stable disease in those with
microsatellite stability [51].
APOBEC family members, mutational burden, the role of
the immune system and its use as a predictor of response
to checkpoint inhibitors
On average, 2–4 oncogenic driver gene mutations are
present in various tumors [52, 53]. It is not clear yet
whether the extent of driver gene mutations correlates
with overall mutational burden (including passenger mu-
tations) and how this impacts on checkpoint molecule
expression on T-cells.
The AID (activation-induced cytidine deaminase)/
APOBEC (apolipoprotein B mRNA editing enzyme cata-
lytic polypeptide-like) gene family members are cytidine
deaminases causing alterations in DNA and mRNA se-
quences by cytidine-to-uracil (C-U) transitions -with
subsequent conversion of U to thymine (T) during DNA
replication- a process called DNA/mRNA-editing that
results in protection from parasitic viruses as well as
protein and antibody diversity. Loss of cellular control of
APOBEC activities results in DNA hypermutations, pro-
miscuous RNA editing, and ultimately genetic instability
and tumorigenesis (for recent review see [54, 55]). One
of the main functions of AID is to regulate mutations in
immunoglobulin (Ig) heavy and light chain genes during
B-cell development in lymph nodes, thereby creating
antibody diversity. AID also alters gene regulation by
interfering with epigenetic DNA modification. However,
AID is to a certain degree ‘leaky’ and may induce off-
target gene mutations and/or translocations of oncogenes
towards Ig genes, thereby promoting leukemogenesis and/
or lymphomagenesis [56–58]. Similarly, other APOBEC
family members, whose canonical function is to induce
showers of mutations in cDNA intermediates of RNA vi-
ruses, contribute to tumor induction and progression in
many types of neoplasias, including -but not limited to-
chronic lymphocytic leukemia (CLL) and breast cancer
[57–61]. Various members of the AID/APOBEC family
may differ up to tenfold in their mutagenic capacity [62]
and APOBEC enzymes may significantly drive subclonal
evolution and tumor heterogeneity [63]. It is therefore not
surprising that APOBEC family mutational signatures
characterize patients with poor prognosis (eg in multiple
myeloma), mostly via their involvement in generating
translocations, which are often associated with adverse
outcome [64]. In breast cancer, APOBEC-3B expression is
associated with unfavorable clinicopathological features
and poor outcome [65]. In line with these observations,
APOBEC-3B expression has been associated with muta-
tions of p53, as well as of the catalytic subunit of phos-
phatidylinositol 3-kinase [66].
On the other hand, activated members of the APOBEC
family might increase the number of neoantigens, cancer-
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specific T-cell clones and may induce a broader TCR
repertoire. Thus, APOBEC family member expression,
function, or mutational pattern could serve as a biomarker
for the response to checkpoint inhibitors and other immu-
nomodulatory drugs. Initial evidence supporting this hy-
pothesis includes:
a) In non-invasive early urothelial cancers APOBEC-
related mutational signatures were predominantly
seen in high-risk tumors [67].
b) In another small series of urothelial tumors, the
expression of certain APOBEC family members
(A3A, A3D and A3H) was associated with PDL1
positive mononuclear cells infiltrating the tumor and
increased expression of the variants A3F_a and
A3F_b correlated with upregulated expression of
PDL1 on tumor cells [68], indicating that PDL1 may
serve as a therapeutic target. As a side note,
increased expression of A3D and A3H was
associated with a better overall survival (OS) in this
study, which seems paradoxical, or at least cannot be
explained yet. Thus, further investigations
concerning APOBEC expression patterns and
response to checkpoint inhibitors are warranted.
c) In high grade serous ovarian carcinomas APOBEC3
expression was significantly associated with T-cell
infiltration and -seemingly paradoxically- with
improved clinical outcome [69].
d) Furthermore, breast cancer developed more
commonly in women with germline APOBEC3B
(A3B) deleting polymorphisms, but these women
were not subject to unfavorable risk profiles or
worse outcome [65], suggesting potential value for
the determination of A3B deletion status in
predicting response to checkpoint inhibitors.
All of the above data encourage deeper analyses of the
correlation (and presumed interaction) between (i) APO-
BEC family member expression profiles, splice variants
and/or polymorphisms and (ii) mutational burden,
clonal evolution, and effects on expression profiles of
immunomodulatory molecules and their function. This
might lead to a better understanding and fine-tuning of
immunotherapies in cancer.
TCR repertoire and T-cell diversity in predicting response
to immunotherapy
Often, driver gene mutations and associated atypical
proteins remain immunologically silent. In fact, over
90% of cancer cell mutations recognized by CD4+ and
CD8+ T-cells occur in passenger genes [45]. This sug-
gests that the TCR repertoire broadens with increasing
numbers of (passenger) gene mutations, resulting in a
broader pool of T-cell clones capable of fighting cancer
cells. This might be exploited with therapeutic strategies
aimed at reactivating or boosting the host anti-tumor
immune response. Therefore, although the presence of
high mutational burden is generally acknowledged to be
an adverse predictor of outcome across all tumor entitites,
it may predict TCR diversity and thus good response to
checkpoint inhibitors and/or activating immunotherapies.
Indeed, TCR diversity was associated with good clin-
ical outcomes following treatment with the MAb ipili-
mumab targeting CTLA-4 in a small series of melanoma
patients [70]. This was confirmed in conference papers
by others, who show that a TCR diversity score higher
than 20% is necessary for good outcome of melanoma
patients receiving anti-CTLA-4 antibody treatment [71].
Interestingly, an inverse constellation was found for treat-
ment with anti-PD1 antibodies [71]. However, as CTLA-4
blockade itself can broaden the TCR repertoire [72], this
may partly explain the seeming discrepancies. Given the
high number of immunomodulatory ligand/receptor pairs
modifying cancer/T-cell interactions, a thorough investi-
gation of these issues, ideally in prospective clinical trials,
is warranted.
Peripheral blood instead of tissue examinations of
biomarkers
Most analyses of biomarkers thought to predict response
to checkpoint inhibitors are currently performed in pri-
mary samples of tumor tissue. However, tumor biopsies
are sometimes difficult or even impossible to obtain and,
depending on the location of the tumor, may be associ-
ated with relevant side effects such as an increased risk
of bleeding, organ perforation and/or infection, as well
as high medical costs for the procedure itself. In addition,
tissue biopsies usually cannot be performed continuously
during the course of the disease due to these potential
risks. Therefore, the actual status of tumor clone evolution
and expansion or reduction of T-cell clones capable of ac-
tively combating the tumor, remains obscure in patients
treated with checkpoint inhibitors. The provision of a ra-
tionale for therapeutic decision making and the choice of
the optimal immunomodulatory drug most suitable to
fight malignant subclones, would ideally require the serial
analysis of (i) representative tumor DNA from tissue biop-
sies, and (ii) various T-cell subsets from peripheral blood.
Recently, the detection of circulating tumor DNA
(ctDNA) has shown very high identification rates of muta-
tions that were also found in primary tumors using a
deep-coverage (15,000x) next-generation sequencing test
of 70 genes [73].
Nevertheless, it has been shown that 9/10 gastro-
intestinal cancer patients had CD4+ and/or CD8+
tumor infiltrating lymphocytes that recognized 1–3 neo-
epitopes from somatic mutations occurring in the respect-
ive cancers [74]. Moreover, very recently it has been
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demonstrated that circulating PD1+ lymphocytes from
cancer patients were enriched in naturally occurring
tumor-reactive and mutation-specific cells [75]. Ex-
haustion of T-cells has mostly, if not exclusively, been
examined on tumor-infiltrating lymphocytes. Thus, lon-
gitudinal analyses and functional examination of T-cells
during the natural disease course and/or during various
treatment phases are lacking. In fact, it remains unknown
at present, whether there is a correlation between ctDNA
(ie type and frequency of mutations) and peripheral blood
T-cell exhaustion profiles. This underlines the necessity to
characterize peripheral blood T-cells within the frame of
clinical trials that aim to aid the immune system to adapt
to clonal tumor evolution via therapeutic immunoediting.
Synergistic immunotherapeutic opportunities
Interaction between various members of checkpoint
inhibitors or immune-activators
The approach of repressing multiple pathways, or of
combining repressive with immunostimulatory antibodies
seems particulary exciting and is currently investigated in
numerous trials (Table 5). In preclinical studies synergy
for such approaches (eg inhibition of PD1 and activation
of CD137, or combined inhibition of inhibitory checkpoint
molecules) has been demonstrated [76–78]. Early phase I
data support the view that such combinations of re-
pressive with activating MAbs are feasible ([78];
NCT00803374, NCT02253992, NCT00351325). How-
ever, these therapeutic approaches must be viewed with
caution and be closely monitored, given the overwhelming
activation of autoimmunity which could arise.
Data in melanoma have shown that nivolumab out-
competes ipilimumab and that the combination of both
is superior over single treatment strategies [28]. In this
regard it is interesting to note that in a murine model
acquired resistance against anti-PD1 antibodies was ac-
companied by an upregulation of another exhaustion
marker, TIM3. The resistance could be broken by inhib-
ition of TIM3 with a blocking antibody and these pre-
clinical mouse data were supported by in vivo findings
in two lung cancer patients [79]. Therefore the combin-
ation -or sequential application- of eg anti-PD1 or anti-
PDL1 antibodies with anti-TIM3 antibodies is an ap-
proach that should be further evaluated in controlled
clinical trials.
Notably, TIM3 is expressed on tumor-infiltrating Tregs
(CD4+, CD25+, Foxp3+), which suppress CD8+ cytotoxic
T-cells (CTLs) [80]. Blocking of TIM3 would thus reduce
the Treg mediated suppression of (tumor-specific) CTLs
and allow them to target the tumor. However, the degree
to which such an effect might be offset by TIM3 expres-
sion on CD4+ [81] and CD8+ [82] effector T cells remains
to be determined, particularly as TIM3 expression was
also associated with improved survival under certain
conditions [83]. Clearly, a systematic serial analysis of
changes in the expression profiles of immunodulatory
molecules during immunoediting in carcinogenesis, pro-
gression of disease as well as during (effective) treatment
needs to be carried out in individual tumor entities in
order to dissect optimal time points and types of immuno-
logic interventions.
Synergistic opportunities with other therapies
Off-target effects of small molecules on T-cells
Kinase inhibitors might synergize with immunotherapy
in combating cancer, even without direct interaction of
the molecular targets. In fact, phase I clinical trials have
shown a synergy between gefitinib, which targets EGFR
with the PD1 checkpoint inhibitor durvalumab in EGFR
mutated NSCLC patients with ~80% response rates [84].
In addition, drugs targeting the proteins of mutated driver
genes might directly increase the re-activation of the spe-
cific immune system exerted by checkpoint inhibitors. In
part, these effects may be caused by interference of some
kinase inhibitors with signaling pathways essential for
T-cell function, activation, survival and proliferation.
Indeed, it has recently been shown that the mitogen-ac-
tivated protein kinase (MAPK) kinase (MEK) inhibitor
cobimetinib increased major histocomaptibility complex
(MHC) class I molecule expression on cancer cells and in-
duced a 17% response rate in colorectal cancer patients
treated with the anti-PDL1 mAb atezolizumab [85]. Mid-
ostaurin, an flt-3 inhibitor with a broad kinase inhibition
dendrogram, increases OS in AML patients (when added
to daunorubicin and cytarabine) [86], yet does not hamper
TCR signaling or T-cell activation [87]. Its effect on ex-
pression and function of checkpoint molecules on the cell
surface of T-cells of AML patients has not yet been ana-
lyzed, although the combination of flt-3 inhibition with
checkpoint inhibitors is currently being tested in Phase I
to III trials in this disease.
The Bruton’s tryosine kinase (BTK) inhibitor ibrutinib
binds covalently to BTK, thus inhibiting B-cell-receptor-
mediated proliferation, inducing apoptosis and migration
of neoplastic B-cells out of the protective micromilieu of
lymph nodes. The drug has shown impressive efficacy in
CLL [88, 89], particularly in patients with p53 mutations
or deletions. Moreover, ibrutinib also binds to and inhibits
interleukin-2-inducible T-cell kinase (ITK), thereby lead-
ing to a T-helper (Th) cell 1 polarization in vitro and in
vivo, which aids in inducing an anti-tumor immune re-
sponse [90]. When mice carrying aggressive lymphomas,
breast or colon cancers, which all were insensitive towards
ibrutinib treatment, were treated with anti-PDL1 MAb or
a combination of anti-PDL1 MAb and ibrutinib, the
combination showed significantly enhanced efficacy over
anti-PDL1 mAb monotherapy [91]. In addition, murine
and human myeloid-derived suppressor cells, which play a
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relevant role in suppressing an efficient anti-tumor im-
mune reaction, express BTK and ibrutinib has been shown
to eliminate these cells in vivo [92].
In addition, PDL1-exposed lymphocytes cocultured
with melanoma cell lines showed downregulation of
MAPK signaling which could be reverted by the B-Raf
inhibitor vemurafenib in vitro [93]. In murine (trans-
plantation) models for hepatocellular cancer, tumor shrink-
age was induced by sorafenib which was linked to a
downregulation of PD1+/CD8+ and Treg cells in the tumor
microenvironment [94]. In addition, in murine B-Raf wild-
type syngeneic transplantable tumors Raf-kinase inhibitors
paradoxically induced hyperactivation of extracellular-
signal regulated kinase (ERK) signaling and thus increased
T-cell activation and signaling [95]. This may serve as an
explanation for increased anti-tumor activity of the com-
bination of CTLA-4-and Raf-kinase inhibitors in preclinical
models. Little has been done to systematically analyze these
interactions of Raf-kinase with checkpoint inhibitors on a
broader, preclinical level.
Other kinase inhibitors have been shown to increase
tumor cell infiltration by T-cells, as detected in core bi-
opsies of patients, which predicts a more favorable
spontaneous clinical course and better response to neo-
adjuvant Her2-targeting agents in breast cancer [96, 97].
These effects predominantly seem to be reflected by the
CD8+/Treg ratio within the tumor tissue [98].
Likewise, janus kinase 2 (Jak2) mRNA expression in
breast cancer cells was associated with increased numbers
of tumor infiltrating leukocytes and better prognosis [99].
However, Jak2-inhibitors, which aim to suppress the
growth supporting function of this kinase in tumor cells,
are currently tested in clinical trials, but since the detailed
role of Jak2 inhibitors on T-cell activation, exhaustion and
tumor recognition has not yet been fully addressed, a
potential unfavorable effect of Jak2-inhibitors cannot be
excluded [99].
Combination of cytotoxic drugs and checkpoint inhibitors –
novel aspects
It is clear that the current results achieved with check-
point inhibitors in clinical practice are exciting, but far
from being good enough. Therefore, various combinations
with chemotherapy, radiotherapy or endocrine therapy are
currently being tested in clinical trials. This approach was
initially followed only reluctantly due to the widespread
view that these chemotherapeutic drugs suppress the im-
mune system [100]. However, it is becoming increasingly
clear that conventional chemotherapeutics may induce the
expression of neoantigens, induce Th1-differentiation
and/or suppress Tregs. These drugs have thus been
termed ‘immunogenic chemotherapy’ [101], and may
ultimately sensitize tumor cells to checkpoint inhibi-
tors [101–104].
In line with this hypothesis, it was demonstrated in a
systemically progressive melanoma patient that local
radioation therapy induced upregulation of the tumor anti-
gen NY-ESO-1 and resulted in consecutive systemic resen-
sitization towards ipilimumab [105]. This observation was
later confirmed in a larger number of patients [106].
Other drugs such as hypomethylating agents may also
show additive immunomodulatory effects with checkpoint
inhibitors, via upregulation of MHC-I on the neoplastic
myeloid-derived suppressor cells (for review see [107]). In
this regard, the combination of anti-PD1 with anti-CTLA-4
antibodies and 5-azacytidine as well as a histon-deacetylase
inhibitor completely eradicated murine breast and colorec-
tal cancer cells in vivo [107].
The influence of the gut microbiota on the immune
response
Gut microbiota, their development during treatment with
chemotherapy and immunomodulators and their influence
on the effect of checkpoint inhibitors
Gut microbiota comprise several trillions of microor-
ganisms with a weight of 2 kg (reviewed in [108]).
These microorganisms include bacteria, archaea, eukarya
and viruses, with the main phyla being firmicutes, bacter-
oidetes and actinobacteria [108]. Of note, significant in-
terindividual differences in the species and functional
composition of the human enterotypes may result from
long-term dietary habits [109, 110]. More importantly,
gut colonization essentially influences the development
of the immune system [111, 112], as seen in inoculation
experiments using germ-free mouse models [113–115],
and gut microbiota have been reported to be centrally
involved in carcinogenesis [116, 117], eg in colorectal
cancer (for reviews see [118, 119]). Alterations in the
composition of gut microbiota have also been shown to
exert systemic effects by modulating estrogen metabolism,
thereby affecting women’s risk of developing postmeno-
pausal estrogen receptor-positive breast cancer (reviewed
in [120]). In addition, certain gut microbiota can induce
DNA double-strand breaks and thus adversely influence
the genomic stability of intestinal epithelial cells in vitro
(eukaryotic cell lines) [121] and in vivo (mouse model)
[122]. In addition, gut microbiota may also exert an influ-
ence on epigenetic modifications, and can thus influence
inflammatory and immunological reactions (reviewed in
[108]), and also directly modulate endogenous T-cell im-
mune responses in mice [123].
Gut microbiota also seem to be involved in the regu-
lation of extrathymic differentiation of Tregs in vitro
and in vivo [124] and Th1 infiltration into cancer tis-
sues following treatment with cyclophosphamide. Anti-
biotic treatment –by subsequent changes in gut microbiota–
may turn down the effect of immunostimulation exerted by
these drugs. In turn, microbiotic constitution within the gut
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has been shown to be modified in number and class distribu-
tion by cytotoxic drugs, including irinotecan, 5-fluorouracil
(reviewed in [125]), and others (reviewed in [108]). Vice
versa, the microbiota may also be indispensible for the in
vivo anti-tumoral effects of certain cytotoxic drugs such as
cyclophosphamide [126] or platinum salts [127] as observed
in mouse models. For example, gut microbiota have been
shown to be involved in the metabolization of cytotoxic
drugs (reviewed in [108]) and in modifying local toxicity of
anticancer drugs in vivo [128–130].
Recently it was also reported that PD1−/− mice have
altered composition of the gut microbiota [131], and
that the efficacy of anti-CTLA-4 treatment in animals
and patients with metastatic melanoma and NSCLC
may depend on the constitution of gut bacteria [132].
Studying the interactions between gut microbiota and
(i) the efficacy of conventional cytotoxic anticancer
drugs, and (ii) immune cells capable of targeting the
tumor, are expected to increase our understanding of
how one might best therapeutically modulate antitumor
immune responses.
Conclusion
In summary, despite the clinical benefit observed in a rele-
vant proportion of patients by targeted immune check-
point modulation, this field of research is still in its
infancy. However, our increasing understanding of tumor
immunology in general, and the immunoediting process
exerted by cancer cells in particular, opens a wide window
of opportunities to improve therapeutic immunomodula-
tory approaches against cancer, making translational
science in this exciting field more important than ever.
Abbreviations
A3B: APOBEC3B; AID: Activation-induced cytidine deaminase; AML: Acute
myeloid leukemia; APOBEC: Apolipoprotein B mRNA editing enzyme catalytic
polypeptide-like; BTK: Bruton’s tryosine kinase; BTLA: B- and T-lymphocyte at-
tenuator; CLL: Chronic lymphocytic leukemia; ctDNA: Circulating tumor DNA;
CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; CTLs: Cytotoxic
T-cells; EGFR: Epidermal growth factor receptor; ERK: Extracellular-signal
regulated kinase; GITR: Glucocorticoid-induced TNFR family related gene;
HVEM: Herpesvirus entry mediator; ICOS: Inducible T-cell costimulator;
ILA: Induced by lymphocyte activation; ITK: Interleukin-2-inducible T-cell kin-
ase; Jak2: Janus kinase 2; LAG3: Lymphocyte activation gene 3;
MAb: Monoclonal antibody/antibodies; MAPK: Mitogen-activated protein
kinase; MEK: Mitogen-activated protein kinase kinase; MHC: Major
histocomaptibility complex; NSCLC: Non-small-cell lung cancer; OS: Overall
survival; PD1: Programmed death 1; PDL1: PD1 ligand; TAA: Tumor-associated
antigens; TCR: T-cell receptor; Th: T-helper; TIGIT: T-cell immunoreceptor with
Ig and ITIM domains; TIM3: T-cell immunoglobulin and mucin protein 3;
TNFR: Tumor necrosis factor receptor; Tregs: Regulatory T-cells;
TREML-2: Trem-like transcript 2 protein; TSA: Tumor-specific (neo)antigens;
VISTA: V-domain Ig suppressor of T-cell activation
Acknowledgements
The authors would like to acknowledge and thank: Keri Davies from FireKite,
an Ashfield company, part of UDG Healthcare plc, editing of the figures to
the required journal format; the Province of Salzburg and the Austrian Science
fund (FWF): W 1213 and P 24100 for funding.
Funding
Austrian Science fund (FWF) W 1213 and P 24100 to RG and W 1213 to TNH.
Availability of data and materials
Not applicable.
Authors’ contributions




The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Third Medical Department with Hematology, Medical Oncology,
Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center,
Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, A-5020
Salzburg, Austria. 2Salzburg Cancer Research Institute (SCRI) - Laboratory for
Immunological and Molecular Cancer Research (LIMCR), Salzburg, Austria.
3Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Study Group,
Salzburg, Austria. 4Cancer Cluster Salzburg (CCS), Salzburg, Austria.
Received: 21 October 2016 Accepted: 6 December 2016
References
1. Coley II WB. Contribution to the knowledge of Sarcoma1. Ann Surg.
1891;14(3):199–220.
2. Galvani DW, Cawley JC. The current status of interferon alpha in haemic
malignancy. Blood Rev. 1990;4(3):175–80.
3. Toren A, et al. Role of interleukin-2 in human hematological malignancies.
Med Oncol. 1995;12(3):177–86.
4. Kruit WH, et al. High-dose regimen of interleukin-2 and interferon-alpha in
combination with lymphokine-activated killer cells in patients with metastatic
renal cell cancer. J Immunother. 1997;20(4):312–20.
Burning questions for translational research
 Which factors could serve as predictors of response to
checkpoint mediators?
 At which time points and from which source(s) (ie
peripheral blood or tissue biopsy) should the analysis of
potential predictors/biomarkers be performed?
 Which combinations of checkpoint mediators with other
therapies seem promising?
 Are the best effects of checkpoint mediators achieved using
combinational or sequential approaches?
 What are the optimal time points for which type of
immunologic intervention(s)?
 Which biological interactions with the tumor
microenvironment might affect the response to checkpoint
mediators?
Greil et al. Cell Communication and Signaling  (2017) 15:5 Page 13 of 16
5. Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients
with metastatic melanoma: analysis of 270 patients treated between 1985
and 1993. J Clin Oncol. 1999;17(7):2105–16.
6. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med.
2012;366(21):2008–16.
7. Maximiano S, et al. Trastuzumab in the treatment of breast cancer. BioDrugs.
2016;30(2):75–86.
8. Goldstein DA, et al. Metastatic colorectal cancer: a systematic review of the
value of current therapies. Clin Colorectal Cancer. 2016;15(1):1–6.
9. Lonial S, et al. Daratumumab monotherapy in patients with treatment-
refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2
trial. Lancet. 2016;387(10027):1551–60.
10. Deng C, Pan B, O’Connor OA. Brentuximab vedotin. Clin Cancer Res.
2013;19(1):22–7.
11. Loke J, et al. Mylotarg has potent anti-leukaemic effect: a systematic review
and meta-analysis of anti-CD33 antibody treatment in acute myeloid
leukaemia. Ann Hematol. 2015;94(3):361–73.
12. Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast
cancer. N Engl J Med. 2012;367(19):1783–91.
13. ADC Shows Effectiveness in SCLC. Cancer Discov. 2015;5(12):OF4.
http://dx.doi.org/10.1158/2159-8290.CD-NB2015-144.
14. Kadin ME, Vonderheid EC. Targeted therapies: Denileukin diftitox–a step
towards a ‘magic bullet’ for CTCL. Nat Rev Clin Oncol. 2010;7(8):430–2.
15. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating
immunity’s roles in cancer suppression and promotion. Science. 2011;
331(6024):1565–70.
16. Greil R, et al. Tuning the rheostat of the myelopoietic system via Fas and
TRAIL. Crit Rev Immunol. 2003;23(4):301–22.
17. Greil R, et al. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic
disorders: pathways, targets, and therapeutic tools. J Leukoc Biol.
2003;74(3):311–30.
18. Tinhofer I, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to
the killing efficacy of Fas (Apo-1/CD95) ligand + tumor cells in B chronic
lymphocytic leukemia. Blood. 1998;91(11):4273–81.
19. Villunger A, et al. Drug-induced apoptosis is associated with enhanced Fas
(Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/
CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res.
1997;57(16):3331–4.
20. Villunger A, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on
multiple myeloma cells: a potential mechanism of tumor-induced suppression
of immune surveillance. Blood. 1997;90(1):12–20.
21. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion.
Nat Rev Immunol. 2015;15:486–99.
22. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9.
23. Topalian SL, et al. Mechanism-driven biomarkers to guide immune
checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87.
24. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and
autoimmunity. Immunol Rev. 2010;236:219–42.
25. Pleyer L, Valent P, Greil R. Mesenchymal Stem and Progenitor Cells in Normal
and Dysplastic Hematopoiesis-Masters of Survival and Clonality? Int J Mol Sci.
2016;17(7):1009.
26. Eggermont AM, et al. Adjuvant ipilimumab versus placebo after complete
resection of high-risk stage III melanoma (EORTC 18071): a randomised,
double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.
27. Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in
untreated melanoma. N Engl J Med. 2015;372(21):2006–17.
28. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or
Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270–1.
29. Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a
randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.
30. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF
mutation. N Engl J Med. 2015;372(4):320–30.
31. Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015;372(26):2521–32.
32. Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1)
in melanoma. N Engl J Med. 2013;369(2):134–44.
33. Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell
Non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
34. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous
Non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.
35. Gillison ML, et al. Abstract CT099: Nivolumab (nivo) vs investigator’s choice
(IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC): CheckMate-141. 2016.
36. Motzer RJ, et al. Nivolumab versus Everolimus in Advanced Renal-Cell
Carcinoma. N Engl J Med. 2015;373(19):1803–13.
37. Rosenberg, J.E. et al. PD-L1 expression, Cancer Genome Atlas (TCGA)
subtype, and mutational load as independent predictors of response to
atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
ASCO Meeting Abstracts, 2016. 34(15_suppl): p. 104.
38. Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory
Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.
39. Armand P. et al. Programmed Death-1 Blockade With Pembrolizumab in
Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
J Clin Oncol. 2016;34(31):3733–39.
40. Nishimura H, et al. Development of lupus-like autoimmune diseases by
disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
Immunity. 1999;11(2):141–51.
41. Tai X, et al. Induction of autoimmune disease in CTLA-4−/− mice depends
on a specific CD28 motif that is required for in vivo costimulation. Proc Natl
Acad Sci U S A. 2007;104(34):13756–61.
42. Croft M. The role of TNF superfamily members in T-cell function and diseases.
Nat Rev Immunol. 2009;9(4):271–85.
43. To PD-L1 or Not to PD-L1: That Is the Question | Cancer Commons. 2016;
Available from: https://www.cancercommons.org/2015/09/09/to-pd-l1-or-
not-to-pd-l1-that-is-the-question/. Accessed 11 Oct 2016.
44. Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody
MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
45. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy.
Science. 2015;348(6230):69–74.
46. George T.J. et al. Tumor mutational burden as a potential biomarker for
PD1/PD-L1 therapy in colorectal cancer. ASCO Meeting Abstracts,
2016. 34(15_suppl): p. 3587.
47. Rizvi NA, et al. Cancer immunology. Mutational landscape determines
sensitivity to PD-1 blockade in non-small cell lung cancer. Science.
2015;348(6230):124–8.
48. Rosenberg JE, et al. Atezolizumab in patients with locally advanced and
metastatic urothelial carcinoma who have progressed following treatment
with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet. 2016;387(10031):1909–20.
49. Singh PP, et al. Immune checkpoints and immunotherapy for colorectal
cancer. In: Gastroenterol Rep (Oxf). 2015. p. 289–97.
50. Koopman M, et al. Deficient mismatch repair system in patients with
sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266–73.
51. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N
Engl J Med. 2015;372(26):2509–20.
52. Ali SM, et al. Prospective comprehensive genomic profiling of advanced
gastric carcinoma cases reveals frequent clinically relevant genomic
alterations and new routes for targeted therapies. Oncologist.
2015;20(5):499–507.
53. Papaemmanuil E, et al. Genomic classification and prognosis in acute
myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.
54. Salter JD, Bennett RP, Smith HC. The APOBEC protein family: united by
structure, divergent in function. Trends Biochem Sci. 2016;41(7):578–94.
55. Knisbacher BA, Gerber D, Levanon EY. DNA editing by APOBECs: a genomic
preserver and transformer. Trends Genet. 2016;32(1):16–28.
56. Robbiani DF, Nussenzweig MC. Chromosome translocation, B cell lymphoma,
and activation-induced cytidine deaminase. Annu Rev Pathol. 2013;8:79–103.
57. Rebhandl S, et al. APOBEC3 signature mutations in chronic lymphocytic
leukemia. Leukemia. 2014;28(9):1929–32.
58. Rebhandl S, et al. Alternative splice variants of AID are not stoichiometrically
present at the protein level in chronic lymphocytic leukemia. Eur J Immunol.
2014;44(7):2175–87.
59. Roberts SA, et al. An APOBEC cytidine deaminase mutagenesis pattern is
widespread in human cancers. Nat Genet. 2013;45(9):970–6.
60. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in
multiple human cancers. Nat Genet. 2013;45(9):977–83.
61. Morganella S, et al. The topography of mutational processes in breast
cancer genomes. Nat Commun. 2016;7:11383.
62. Chan K, et al. An APOBEC3A hypermutation signature is distinguishable
from the signature of background mutagenesis by APOBEC3B in human
cancers. Nat Genet. 2015;47(9):1067–72.
Greil et al. Cell Communication and Signaling  (2017) 15:5 Page 14 of 16
63. Swanton C, et al. APOBEC enzymes: mutagenic fuel for cancer evolution
and heterogeneity. Cancer Discov. 2015;5(7):704–12.
64. Walker BA, et al. APOBEC family mutational signatures are associated with
poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.
65. Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer
reflects cellular proliferation, while a deletion polymorphism is associated
with immune activation. Proc Natl Acad Sci U S A. 2015;112(9):2841–6.
66. Henderson S, et al. APOBEC-mediated cytosine deamination links PIK3CA
helical domain mutations to human papillomavirus-driven tumor
development. Cell Rep. 2014;7(6):1833–41.
67. Hedegaard J, et al. Comprehensive transcriptional analysis of early-stage
urothelial carcinoma. Cancer Cell. 2016;30(1):27–42.
68. Mullane SA, et al. Correlation of apobec mrna expression with overall
survival and pd-l1 expression in urothelial carcinoma. Sci Rep. 2016;6:27702.
69. Leonard B, et al. APOBEC3G expression correlates with T-cell infiltration and
improved clinical outcomes in high-grade serous ovarian carcinoma. Clin
Cancer Res. 2016;22(18):4746–55.
70. Postow MA, et al. Peripheral T cell receptor diversity is associated with
clinical outcomes following ipilimumab treatment in metastatic melanoma.
J Immunother Cancer. 2015;3:23.
71. Goldinger S.M. et al. The peripheral blood TCR repertoire to facilitate patient
stratification for immune checkpoint blockade inhibition in metastatic
melanoma. ASCO Meeting Abstracts, 2016. 34(15_suppl): p. 3026.
72. Robert L, et al. CTLA4 blockade broadens the peripheral T-cell receptor
repertoire. 2014.
73. Zill, O.A. et al. Somatic genomic landscape of over 15,000 patients with
advanced-stage cancer from clinical next-generation sequencing
analysis of circulating tumor DNA. ASCO Meeting Abstracts,
2016. 34(18_suppl): p. LBA11501.
74. Tran E, et al. Immunogenicity of somatic mutations in human
gastrointestinal cancers. Science. 2015;350(6266):1387–90.
75. Gros A, et al. Selection of circulating PD-1+ lymphocytes from cancer
patients enriches for tumor-reactive and mutation-specific lymphocytes. J
Immunother Cancer. 2015;3 Suppl 2:O2.
76. Fourcade J, et al. Upregulation of Tim-3 and PD-1 expression is associated
with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
J Exp Med. 2010;207(10):2175–86.
77. Woo SR, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically
regulate T-cell function to promote tumoral immune escape. Cancer Res.
2012;72(4):917–27.
78. Márquez-Rodas I, et al. Immune checkpoint inhibitors: therapeutic advances
in melanoma. Ann Transl Med. 2015;3(18):267.
79. Koyama S, et al. Adaptive resistance to therapeutic PD-1 blockade is
associated with upregulation of alternative immune checkpoints. Nat
Commun. 2016;7:10501.
80. Bu M, et al. Ovarian carcinoma-infiltrating regulatory T cells were more
potent suppressors of CD8(+) T cell inflammation than their peripheral
counterparts, a function dependent on TIM3 expression. Tumour Biol.
2016;37(3):3949–56.
81. Moorman JP, et al. Tim-3 pathway controls regulatory and effector T cell
balance during hepatitis C virus infection. 2012.
82. Sakuishi K, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell
exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–94.
83. Farren MR, et al. Systemic immune activity predicts overall survival in
treatment-naive patients with metastatic pancreatic cancer. Clin Cancer Res.
2016;22(10):2565–74.
84. Gibbons DL, et al. 57O Efficacy, safety and tolerability of MEDI4736
(durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1
(PD-L1) antibody, combined with gefitinib (G): A phase I expansion in
TKI-naive patients (pts) with EGFR mutant NSCLC. J Thorac Oncol.
2016;11(4 Suppl):S79.
85. Bendell J.C. et al. Clinical activity and safety of cobimetinib (cobi) and
atezolizumab in colorectal cancer (CRC). ASCO Meeting Abstracts,
2016. 34(15_suppl): p. 3502.
86. Stone RM et al. The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival
Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine
(C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance
(maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients
(pts) Age 18–60 with FLT3 Mutations (muts): An International Prospective
Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY
[Alliance]). 2015.
87. Wolleschak D, et al. Clinically relevant doses of FLT3-kinase inhibitors
quizartinib and midostaurin do not impair T-cell reactivity and function.
Haematologica. 2014;99(6):e90–3.
88. Burger JA, et al. Ibrutinib as initial therapy for patients with chronic
lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.
89. Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic
lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.
90. Dubovsky JA, et al. Ibrutinib is an irreversible molecular inhibitor of ITK
driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–49.
91. Sagiv-Barfi I, et al. Therapeutic antitumor immunity by checkpoint blockade
is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad
Sci U S A. 2015;112(9):E966–72.
92. Stiff A, et al. Myeloid-Derived Suppressor Cells Express Bruton’s Tyrosine
Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Cancer Res. 2016;76(8):2125–36.
93. Atefi M, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in
melanoma. Clin Cancer Res. 2014;20(13):3446–57.
94. Chen ML, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions
of effector T cells in tumor microenvironment to augment antitumor
immunity. Int J Cancer. 2014;134(2):319–31.
95. Callahan MK, et al. Paradoxical activation of T cells via augmented ERK
signaling mediated by a RAF inhibitor. Cancer Immunol Res. 2014;2(1):70–9.
96. Salgado R, et al. Tumor-Infiltrating Lymphocytes and Associations With
Pathological Complete Response and Event-Free Survival in HER2-Positive
Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A
Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015;1(4):448–54.
97. Denkert C, et al. Tumor-infiltrating lymphocytes and response to
neoadjuvant chemotherapy with or without carboplatin in human
epidermal growth factor receptor 2-positive and triple-negative primary
breast cancers. J Clin Oncol. 2015;33(9):983–91.
98. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T
cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer
Immunol Immunother. 2011;60(7):909–18.
99. Miller CP, et al. JAK2 expression is associated with tumor-infiltrating
lymphocytes and improved breast cancer outcomes: implications for
evaluating JAK2 inhibitors. Cancer Immunol Res. 2014;2(4):301–6.
100. Zitvogel L, et al. Immunological aspects of cancer chemotherapy. Nat Rev
Immunol. 2008;8(1):59–73.
101. Pfirschke C, et al. Immunogenic chemotherapy sensitizes tumors to
checkpoint blockade therapy. Immunity. 2016;44(2):343–54.
102. Zitvogel L, et al. The anticancer immune response: indispensable for
therapeutic success? J Clin Invest. 2008;118(6):1991–2001.
103. Galluzzi L, et al. Immunological effects of conventional chemotherapy and
targeted anticancer agents. Cancer Cell. 2015;28(6):690–714.
104. Melero I, et al. Evolving synergistic combinations of targeted
immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–72.
105. Postow MA, et al. Immunologic correlates of the abscopal effect in a patient
with melanoma. N Engl J Med. 2012;366(10):925–31.
106. Chandra RA, et al. A systematic evaluation of abscopal responses following
radiotherapy in patients with metastatic melanoma treated with ipilimumab.
Oncoimmunology. 2015;4(11):e1046028.
107. Kim K, et al. Eradication of metastatic mouse cancers resistant to immune
checkpoint blockade by suppression of myeloid-derived cells. Proc Natl
Acad Sci U S A. 2014;111(32):11774–9.
108. Viaud S, et al. Gut microbiome and anticancer immune response: really hot
Sh*t! Cell Death Differ. 2015;22(2):199–214.
109. Arumugam M, et al. Enterotypes of the human gut microbiome. Nature.
2011;473(7346):174–80.
110. Gophna U. Microbiology. The guts of dietary habits. Science.
2011;334(6052):45–6.
111. Dimmitt RA, et al. The role of postnatal acquisition of the intestinal
microbiome in the early development of immune function. J Pediatr
Gastroenterol Nutr. 2010;51(3):262–73.
112. Kau AL, et al. Human nutrition, the gut microbiome and the immune
system. Nature. 2011;474:327–36.
113. Neumann E, et al. Monoassociation with Lactobacillus acidophilus UFV-
H2b20 stimulates the immune defense mechanisms of germfree mice. Braz
J Med Biol Res. 1998;31(12):1565–73.
114. Duarte R, et al. Influence of normal microbiota on some aspects of the
immune response during experimental infection with Trypanosoma cruzi in
mice. J Med Microbiol. 2004;53(Pt 8):741–8.
Greil et al. Cell Communication and Signaling  (2017) 15:5 Page 15 of 16
115. Oliveira MR, et al. Germ-free mice produce high levels of interferon-gamma
in response to infection with Leishmania major but fail to heal lesions.
Parasitology. 2005;131(Pt 4):477–88.
116. Round JL, Mazmanian SK. The gut microbiome shapes intestinal immune
responses during health and disease. Nat Rev Immunol. 2009;9(5):313–23.
117. Russo E, et al. The interplay between the microbiome and the adaptive
immune response in cancer development. Therap Adv Gastroenterol.
2016;9(4):594–605.
118. Tjalsma H, et al. A bacterial driver-passenger model for colorectal cancer:
beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–82.
119. Boleij A, Tjalsma H. Gut bacteria in health and disease: a survey on the
interface between intestinal microbiology and colorectal cancer. Biol Rev
Camb Philos Soc. 2012;87(3):701–30.
120. Kwa M et al. The Intestinal Microbiome and Estrogen Receptor-Positive
Female Breast Cancer. J Natl Cancer Inst. 2016;108(8). doi:10.1093/jnci/
djw029.
121. Nougayrede JP, et al. Escherichia coli induces DNA double-strand breaks in
eukaryotic cells. Science. 2006;313(5788):848–51.
122. Mangerich A, et al. Infection-induced colitis in mice causes dynamic and
tissue-specific changes in stress response and DNA damage leading to
colon cancer. Proc Natl Acad Sci U S A. 2012;109(27):E1820–9.
123. Wu S, et al. A human colonic commensal promotes colon tumorigenesis via
activation of T helper type 17 T cell responses. Nat Med. 2009;15(9):1016–22.
124. Arpaia N, et al. Metabolites produced by commensal bacteria promote
peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–5.
125. Zitvogel L, et al. Cancer and the gut microbiota: an unexpected link. Sci
Transl Med. 2015;7(271):271ps1.
126. Viaud S, et al. The intestinal microbiota modulates the anticancer immune
effects of cyclophosphamide. Science. 2013;342(6161):971–6.
127. Iida N, et al. Commensal bacteria control cancer response to therapy by
modulating the tumor microenvironment. Science. 2013;342(6161):967–70.
128. Stringer AM, et al. Faecal microflora and beta-glucuronidase expression are
altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther.
2008;7(12):1919–25.
129. Gupta E, et al. Metabolic fate of irinotecan in humans: correlation of
glucuronidation with diarrhea. Cancer Res. 1994;54(14):3723–5.
130. Takasuna K, et al. Involvement of beta-glucuronidase in intestinal microflora
in the intestinal toxicity of the antitumor camptothecin derivative irinotecan
hydrochloride (CPT-11) in rats. Cancer Res. 1996;56(16):3752–7.
131. Maruya M, et al. Impaired selection of IgA and intestinal dysbiosis
associated with PD-1-deficiency. Gut Microbes. 2013;4(2):165–71.
132. Vétizou M, et al. Anticancer immunotherapy by CTLA-4 blockade relies on
the gut microbiota. Science. 2015;350(6264):1079–84.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Greil et al. Cell Communication and Signaling  (2017) 15:5 Page 16 of 16
